Exclusive | MDMA-assisted therapy could get FDA approval as soon as January, top advocate predicts but theres a major problem looming

A drug once synonymous with rave culture could soon be making its way into a very different setting: the therapist’s office.A leading psychedelics advocate is “very optimistic” the Food and Drug Administration could approve MDMA-assisted therapy for post-traumatic stress disorder as early as January.But even if the treatment gets the green light, a major roadblock could stand between the psychedelic and the millions of Americans who could benefit from a new path to relief.MDMA, also called ecstasy and molly, is known for its euphoric effects and reputation as a party drug.It has no FDA-approved medical uses, though researchers have spent years exploring whether it could serve as a mental health treatment — with promising results.In a 2021 clinical trial conducted by the nonprofit Multidisciplinary Association for Psychedelic Studies (MAPS), people with PTSD who received MDMA alongside psychotherapy were twice as likely to recover as those who received psychotherapy with a placebo.PTSD, which can develop after experiencing or witnessing a traumatic event, can leave sufferers battling flashbacks, nightmares, severe anxiety and intrusive thoughts, according to the Mayo Clinic.For patients who’ve exhausted traditional options, advocates have argued that MDMA-assisted therapy could offer a new lifeline.Yet the road to approval has been anything but a smooth ride.Two years ago, Lykos Therapeutics looked like a frontrunner to bring MDMA into mainstream medicine.

Then, in August 2024, the FDA dashed those hopes, rejecting the company’s application over questions about the reliability of its clinical trial data, potential safety risks and concerns that the studies didn’t adequately demonstrate the therapy’s effectiveness.The agency called for another Phase 3 trial to help address those apprehensions.The decision dealt a major blow to psychedelic researchers, patient advocates and veterans’ groups who’d championed the drug.Had it been approved, it would ...